O Shevah1, Z Laron. 1. Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, 14 Kaplan Street, Petah-Tikva 49202, Israel.
Abstract
OBJECTIVE: Overexpression of IGF-I occurs in tumors diagnosed in childhood (osteosarcoma, Wilms tumor, neuroblastoma, etc.) and in adults (breast, ovaries, colon and prostate cancer). The aim of our study was to establish the prevalence of malignancies in states of congenital IGF-I deficiency. SUBJECTS: We surveyed 222 patients with congenital IGF-I deficiency (Laron syndrome, GH gene deletion, GHRH receptor defects and IGF-I resistance) and 338 first and second-degree relatives. RESULTS: None of the IGF-I deficient patients had cancer, whereas 9-24% of the family members had a history of malignancy. CONCLUSIONS: Congenital IGF-I deficiency acts as a protecting factor for the development of cancer.
OBJECTIVE: Overexpression of IGF-I occurs in tumors diagnosed in childhood (osteosarcoma, Wilms tumor, neuroblastoma, etc.) and in adults (breast, ovaries, colon and prostate cancer). The aim of our study was to establish the prevalence of malignancies in states of congenital IGF-I deficiency. SUBJECTS: We surveyed 222 patients with congenital IGF-I deficiency (Laron syndrome, GH gene deletion, GHRH receptor defects and IGF-I resistance) and 338 first and second-degree relatives. RESULTS: None of the IGF-Ideficientpatients had cancer, whereas 9-24% of the family members had a history of malignancy. CONCLUSIONS:Congenital IGF-I deficiency acts as a protecting factor for the development of cancer.
Authors: Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson Journal: J Clin Endocrinol Metab Date: 2015-04-03 Impact factor: 5.958
Authors: Darlene E Berryman; Jens Sandahl Christiansen; Gudmundur Johannsson; Michael O Thorner; John J Kopchick Journal: Growth Horm IGF Res Date: 2008-08-16 Impact factor: 2.372
Authors: Manuel H Aguiar-Oliveira; Francielle T Oliveira; Rossana M C Pereira; Carla R P Oliveira; Amanda Blackford; Eugenia H O Valenca; Elenilde G Santos; Miburge B Gois-Junior; Rafael A Meneguz-Moreno; Vanessa P Araujo; Luis A Oliveira-Neto; Roque P Almeida; Mário A Santos; Natalia T Farias; Debora C R Silveira; Gabriel W Cabral; Flavia R Calazans; Juliane D Seabra; Tiago F Lopes; Endrigo O Rodrigues; Livia A Porto; Igor P Oliveira; Enaldo V Melo; Marco Martari; Roberto Salvatori Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958